Blue Vision (PEG.CO) Stock Analysis & AI Equity Report
Blue Vision (PEG.CO) overview
Blue Vision (PEG.CO) stock analysis and AI equity research. For the latest completed financial year, 2022, Blue Vision reported revenue of DKK 0m and operating profit of DKK -4.3m; the year-end share price was N/A and market capitalisation was N/A. Blue Vision is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Blue Vision's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-12. Data will be refreshed during report generation.
About Blue Vision
Blue Vision A/S, now operating as Pharma Equity Group A/S, is a Danish listed company focused on advancing pharmaceutical development through its subsidiary Reponex Pharmaceuticals A/S. Its activities center on supporting and financing drug-candidate development, including clinical and regulatory work on pipeline projects, and on building value through future licensing or strategic partnering.
Generate the Blue Vision report
Blue Vision is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Blue Vision and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.